Antimicrobial resistance: Why it matters and what can be done
Antimicrobial resistance (AMR) — often called antibiotic resistance when referring to bacterial infections — is one of the most urgent and persistent threats to global health. As microbes adapt to the drugs designed to kill them, common infections become harder to treat, routine medical procedures grow riskier, and health systems face rising costs and strain. Understanding the drivers of AMR and the practical steps that slow its spread are essential for clinicians, policymakers, farmers, and individuals alike.
What drives resistance
– Overuse and misuse of antimicrobials in human medicine is a primary contributor. Prescribing antibiotics for viral infections, using broad-spectrum agents when narrow options suffice, and incomplete courses all encourage resistant strains to emerge.
– Widespread use of antibiotics in animal agriculture — for growth promotion or routine disease prevention — selects for resistant bacteria that can spread to humans through food, contact, or the environment.
– Poor infection prevention and sanitation amplify spread.
Crowded healthcare settings, inadequate water and sanitation, and suboptimal hygiene provide ideal conditions for resistant pathogens to move between people.
– Limited access to rapid diagnostic tools leads to empirical treatment and unnecessary antibiotic use. When clinicians can’t quickly distinguish bacterial from viral infections, they may prescribe “just in case.”
– A slow pipeline of new antibiotics and antimicrobial alternatives allows resistance to outpace innovation. Scientific, regulatory, and economic hurdles make investment in new classes of antimicrobials challenging.
Why it matters
AMR erodes decades of medical progress.
Procedures that rely on effective antibiotics — surgeries, chemotherapy, care for preterm infants — become riskier. Resistant infections increase illness severity, lengthen hospital stays, and raise healthcare costs. Low-resource settings are often hardest hit, where access to second-line treatments and strong infection control may be limited.
A One Health approach
Addressing AMR requires coordinated action across human, animal, and environmental health — the One Health model. That means integrated surveillance for resistance patterns, harmonized regulations on antibiotic use in livestock, and environmental monitoring for drug residues and resistant genes in wastewater.
Actions that make a difference
– Strengthen antibiotic stewardship in clinics and hospitals: use narrow-spectrum antibiotics where appropriate, follow evidence-based guidelines, and de-escalate therapy when diagnostic results allow.
– Expand rapid diagnostics: point-of-care tests that distinguish bacterial from viral infections reduce unnecessary prescriptions and target therapy more effectively.
– Improve infection prevention and control: hand hygiene, vaccination, safe injection practices, and clean water and sanitation reduce the burden of infection and the need for antibiotics.
– Regulate and reduce non-therapeutic antibiotic use in agriculture, while supporting farmers with alternatives like improved husbandry, vaccination, and better biosecurity.
– Invest in innovation: incentives for new antibiotics, as well as alternative therapies — such as bacteriophages, monoclonal antibodies, and antimicrobial peptides — can diversify the toolkit against resistant pathogens.
– Global cooperation and equitable access: low- and middle-income regions need support for surveillance, laboratory capacity, and access to effective medicines without reliance on last-resort antibiotics.
What individuals can do
Don’t demand antibiotics for viral illnesses, follow prescriptions exactly, complete the full course unless advised otherwise, keep vaccinations up to date, practice good hand hygiene, and support policies that promote responsible antibiotic use.
The path forward combines science, policy, and behavior change.
By embracing stewardship, investing in diagnostics and new therapies, and aligning human, animal, and environmental health efforts, it’s possible to slow resistance and preserve the effectiveness of antimicrobials for future generations. Collective action now determines whether common infections remain manageable or become major obstacles to health and wellbeing.